

Cambridge Enterprise

BIO2023

5th – 8th June 2023

Phil Elstob

Commercialisation Director &
Deputy Head of Life Science
Phil.Elstob@enterprise.cam.ac.uk

Katja Kostelnik

Commercialisation Manager
Katja.Kostelnik@enterprise.cam.ac.uk







Cambridge Enterprise is uniquely positioned with access to ground-breaking technologies and solutions from the University of Cambridge.

Our team partners these with organisations and investors around the world to develop products and services that create positive social change.


Our performance, 2020-21



Knowledge transfer in numbers





Investment in numbers




Novel divinylpyrimidine (DVP) chemistry for antibody-drug conjugation




Novel divinylypyrimidine (DVP) chemistry for antibody-drug conjugation




Trastuzumab



MMAE





Trastuzumab-DVP-MMAE



Novel divinylypyrimidine (DVP) chemistry for antibody-drug conjugation

Trastuzumab-DVP-MMAE



- native antibody
- controlled DAR of 4
- no retro-Michael addition
- on-antibody functionalisation